This inventor holds 1 USPTO granted patent. Top assignee: Amgen Inc.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Steven A. Moore, Jr.: Innovator in Cannabinoid Research
Introduction
Steven A. Moore, Jr. is a notable inventor based in Poway, California. He has made significant contributions to the field of cannabinoid research, particularly through his innovative work on monoclonal antibodies targeting the cannabinoid receptor-1 (CB1). His research holds promise for addressing various health conditions, including obesity and diabetes.
Latest Patents
Moore holds a patent for cannabinoid receptor-1 (CB1) monoclonal antibodies. This patent relates to CB1 receptor antigen-binding proteins, such as antibodies, and outlines methods for utilizing these antibodies. The CB1 receptor antibodies may include antagonistic antibodies that can be employed in the treatment of health conditions that benefit from the antagonism of the CB1 receptor.
Career Highlights
Steven A. Moore, Jr. is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen focuses on advancing research in the field of cannabinoid receptors and their potential therapeutic applications. His innovative approach has positioned him as a key figure in cannabinoid research.
Collaborations
Some of his notable coworkers include Peter Coward and Shi-Yuan Meng. Their collaborative efforts contribute to the ongoing research and development in cannabinoid-related therapies.
Conclusion
Steven A. Moore, Jr. is a pioneering inventor whose work on cannabinoid receptor-1 monoclonal antibodies has the potential to transform treatment options for various health conditions. His contributions to the field of biotechnology are noteworthy and continue to inspire further research and innovation.